Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to assess the safety and effectiveness of the investigational drug repotrectinib in children and young adults with solid tumors that have continued to grow or spread despite treatment. Repotrectinib works by targeting and blocking certain proteins that play a role in cancer growth. Some of these proteins are controlled by the ALK, ROS1, NTRK1, NTRK2, and NTRK3 genes. Researchers also think that combining repotrectinib with the chemotherapy drugs irinotecan and temozolomide may make the treatment more effective.
Researchers want to find the best dose of LY4066434 when given alone and with other drugs to treat solid tumors. The people in this study have cancer that has spread (advanced) or cannot be removed with surgery (inoperable). These include colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, and other solid tumors.
I-DXd is a type of drug called an antibody-drug conjugate (ADC). ADCs are made of a monoclonal antibody linked to a drug. The antibody binds to a protein on cancer cells called B7-H3, which plays a role in cancer cell growth. It then releases the anti-cancer drug to kill the cancer cell. By destroying these cells, I-DXd may help slow or stop the growth of your cancer.
Researchers want to see how well cabozantinib works to treat meningioma, a type of brain tumor. The people in this study have meningiomas that came back or keep growing even after treatment.
Many people who get chemotherapy experience a loss of their period (amenorrhea). They may have menopause-like symptoms such as insomnia, hot flashes, and anxiety. The condition also increases the risk of infertility.
Researchers are assessing JCAR017 in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The people in this study have CLL or SLL that came back or keeps growing after treatment.
The purpose of this study is to assess OBX-115 cellular therapy for people with advanced melanoma or lung cancer. The people in this study have melanoma or non-small cell lung cancer (NSCLC). Their cancers have metastasized (spread) or are inoperable (cannot be taken out with surgery) and keep growing even after treatment.
Researchers want to find the best dose of EVM14 when used alone or with pembrolizumab in people with solid tumors. The people in this study have a solid tumor that keeps growing after treatment and has spread. This study includes people with:
Cells that are "mismatch repair-deficient" (MMR-D) or "microsatellite instability-high" (MSI-H) are unable to repair mistakes made during cell growth. Women with MMR-D/MSI-H endometrial cancer tend not to respond well to the chemotherapy they receive after surgery. Researchers are exploring the use of the immunotherapy TSR-042 (also called dostarlimab) as an alternative to chemotherapy. Radiation therapy is also used after surgery for endometrial cancer.
Chemotherapy can cause symptoms, such as nausea and fatigue, and some patients have difficulty working during this treatment. The purpose of this study is to learn more about how chemotherapy for breast cancer affects patients' employment.
